目的：分析玻璃体腔注射康柏西普治疗视网膜分支静脉阻塞(BRVO)伴黄斑水肿(ME)的疗效及治疗后BCVA的影响因素。

方法：评价2016-01/2018-01在本院接受玻璃体腔注射康柏西普治疗的194例194眼BRVO-ME患者的临床疗效，多因素Logistic回归分析探究治疗后BCVA的影响因素。

结果：患者BCVA(LogMAR)、CMT较治疗前显著下降，其中CMT虽在部分时间节点有回升趋势，但任意时间点的BCVA、CMT均显著低于治疗前(P<0.05)； 多因素Logistic回归分析显示，BRVO-ME分型-缺血型、ME类型-混合型、ELM完整性-缺失、IS/OS缺失均是影响BRVO-ME患者经玻璃体腔内注射康柏西普疗效的独立危险因素，且病程及眼轴长度越长、治疗前 BCVA值越高，经玻璃体腔内注射康柏西普治疗无效的风险越高。

结论：玻璃体腔注射康柏西普治疗BRVO-ME疗效显著且安全性良好，部分患者术后BCVA恢复不佳或受病程、术前BCVA、BRVO-ME分型、ELM及IS/OS完整性等因素影响，治疗前或应充分评估上述影响因素并积极应对，优化疗效。

METHODS: The clinical efficacy of 194 patients 194 eyes with BRVO-ME who underwent intravitreal injection of conbercept in the hospital from January 2016 to January 2018 were evaluated. The influencing factors of BCVA after treatment were analyzed by multivariate Logistic regression analysis.

RESULTS: The minimum resolution angular logarithm(LogMAR)vision of BCVA and retinal thickness(CMT)of macular fovea of the patients were significantly decreased compared with those before treatment. Although CMT showed a recovery trend at some time nodes, BCVA and CMT at any time point were significantly lower than those before treatment(P<0.05). Multiariable Logistic regression analysis showed that BRVO-ME-ischemic type, type of the ME-hybrid, ELM integrity-missing, missing IS/OS are affected patients with BRVO-ME the vitreous cavity of independent risk factors for compaq heap of injection effect, and the longer the course of the disease and the axial length, BCVA before treatment is higher, the vitreous cavity of treated by injection of compaq heap for the higher risk.

CONCLUSION: The curative effect of intravitreal injection of Conbercept is significant on BRVO-ME and safety is good. The poor BCVA recovery in some patients is effected by disease course, BRVO-ME types and other factors. The above factors should be fully evaluated before treatment and active response should be performed, for further optimizing the curative effect.